Clinical trials: Lewy Body Disease, open to volunteers
Lewy Body Dementia (LBD), Alzheimer Dementia (AD)
Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias
This study is being done to research the usefulness of PET/CT imaging for measuring brain inflammation and its relation to Alzheimer's Disease Dementia and related dementias.
- Trial name
- NCT04786223
- Testing
- C-11 ER-176, Blood Test
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Val Lowe
REM Sleep Behavior Disorder, Parkinson Disease
North American Prodromal Synucleinopathy Consortium Stage 2
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
- Conditions
- REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Dementia, Dementia With Lewy Bodies
- Trial name
- NAPS2 (NCT05826457)
- Where
- 9 sites in United States, Canada
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB)
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily…
- Conditions
- Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB), PSP, Lewy Body Dementia (LBD)
- Trial name
- NCT07240805
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- BioSensics
Parkinson Disease (PD)
Validation of α-synuclein Modifications in Parkinson's dIsoRder Evolution
Parkinson's disease (PD) presents a complex challenge due to its progressive neurodegenerative nature, affecting various bodily systems.
- Trial name
- VaMPiRE (NCT06941012)
- Testing
- Blood draw for the laboratory assessment
- Where
- 4 sites in Greece, Italy and 2 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Casa di Cura IGEA
Alzheimer Disease, FTD
Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases
The study aims to use 'omics' sciences, employing the most advanced technologies currently available, in order to identify pathogenic genomic variants, proteins and/or altered molecular pathways in neurodegenerative diseases and…
- Conditions
- Alzheimer Disease, FTD, Young-onset Dementia, MCI
- Trial name
- NeurOmics (NCT07235111)
- Where
- Italy
- Volunteers
- 1,200 people
- Sponsor
- Ospedale Policlinico San Martino
Endometrial Cancer
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment…
- Trial name
- DE-01 (NCT06989112)
- Testing
- Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab
- Where
- 257 sites in United States, Australia and 21 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Lewy Body Disease, Lewy Body Dementia
Visual Hallucinations in Lewy Body Diseases
The goal of this basic experimental study involving humans (BESH) protocol is to improve the understanding of neural mechanisms underlying visual hallucinations in Lewy Body diseases to inform future treatment developments.
- Conditions
- Lewy Body Disease, Lewy Body Dementia, Parkinson Disease, Parkinson Disease Dementia
- Trial name
- NCT07849413
- Testing
- Behavioral Tasks, MRI/MEG Scans
- Where
- United States
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Parkinson Disease, REM Sleep Behavior Disorder
Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder
The study aims to systematically document the course of REM sleep behavior disorder (RBD) and investigate possible clinical and imaging biomarkers for disease progression and conversion risk to Parkinson's disease (PD), dementia…
- Conditions
- Parkinson Disease, REM Sleep Behavior Disorder, Dementia, Lewy Body
- Trial name
- NUK-RBD (NCT06629207)
- Testing
- PET/CT with 18-FDG, SPECT : 123 I-FP-CIT (DATSCAN), MRI
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Vascular Parkinsonism, Drug-induced Parkinsonism
AI-Enhanced Optimization of Acute Levodopa Challenge Test
A quantitative evaluation method was developed for Parkinson's disease and other atypical parkinonism by integrating an innovative motor paradigm with perception technologies and artificial intelligence.
- Conditions
- Vascular Parkinsonism, Drug-induced Parkinsonism, Corticobasal Degeneration (CBD), Parkinson Disease (PD)
- Trial name
- NCT06949865
- Testing
- video recording
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Beijing Tiantan Hospital
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Alzheimer's Disease (AD), Frontotemporal Dementia (FTD)
Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence Models
This multicenter study aims to characterize the language profiles of patients with various neurodegenerative diseases, including Alzheimer's disease (AD), Primary Progressive Aphasia (PPA), behavioral variant Frontotemporal…
- Conditions
- Alzheimer's Disease (AD), Frontotemporal Dementia (FTD), Parkinsons Disease (PD), Lewy Body Dementia
- Trial name
- AILAN (NCT07906769)
- Testing
- Speech and language Test to support clinical diagnosis
- Where
- Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Tauopathies
Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 11C HY-2-15. The goal of this radiotracer is to quantify alpha-synuclein that is abnormally deposited in the brain of people with…
- Trial name
- NCT06032026
- Testing
- 11C-HY-2-15 PET, brain MRI, Amyloid PET scan
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Dementia, Frontotemporal, Alzheimer Dementia (AD)
Investigating Genetic Status in Patients Presenting to Clinic
The causes of neurodegenerative dementias such as Frontotemporal Dementia, Lewy Body Disease and Alzheimer's disease are still largely unknown.
- Conditions
- Dementia, Frontotemporal, Alzheimer Dementia (AD), Lewy Body Dementia (LBD)
- Trial name
- NCT05911932
- Testing
- Biosample collection.
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lewy Body Disease
Longitudinal Imaging Biomarkers of Disease Progression in DLB
The Researchers are trying to determine the paths of change in imaging biomarkers of Dementia with Lewy bodies (DLB) and their associations with rate of cognitive and functional decline.
- Trial name
- NCT03582488
- Testing
- 18F-Flortaucipir
- Where
- 2 sites in United States
- Volunteers
- 135 people
- Sponsor
- Kejal Kantarci
Lewy Body Disease, Healthy Aging
Language and Lewy Body Diseases: Sentence Comprehension Problems and Modifying Noninvasive Brain Stimulation Treatment
Lewy body diseases (LBDs) represents a group of neurodegenerative disorders characterized by the abnormal accumulation of aggregates of α-synuclein protein leading to the formation of Lewy bodies (LB) and Lewy neurites resulting…
- Trial name
- LANG-LBD (NCT05847985)
- Testing
- transcranial direct current stimulation (tDCS)
- Where
- Czechia
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Masaryk University
Dementia With Lewy Bodies Diagnosis, Significant Cognitive Fluctuations in DLB
Personalized Repetitive Transcranial Magnetic Stimulation (rTMS) in Cognitive Fluctuations of Dementia With Lewy Bodies (DLB): Proof of Concept
The present study is a monocentric, therapeutic clinical trial involving forty patients diagnosed with Dementia with Lewy Bodies (DLB).
- Trial name
- STIMLEWY (NCT05138588)
- Testing
- rTMS
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Strasbourg, France
NSCLC, Non-Small Cell Lung Cancer
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
Background: Immunotherapy is a type of treatment that works by making the body s own immune system stronger. These treatments are used for cancers such as non small cell lung cancer (NSCLC); thymic carcinoma (TC); or metastatic…
- Conditions
- NSCLC, Non-Small Cell Lung Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT07902921
- Testing
- STAR0602, Nivolumab
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- National Cancer Institute (NCI)
Parkinson Disease, Parkinson Disease Dementia
Parkinson's Disease and Movement Disorders Clinical Database
The research database contains demographic and family history information, longitudinal information on the clinical symptoms, neuropsychological profile and treatments, stored biological samples, and brain images of patients with…
- Conditions
- Parkinson Disease, Parkinson Disease Dementia, Lewy Body Parkinson Disease, Lewy Body Dementia With Behavioral Disturbance
- Trial name
- NCT04997642
- Testing
- neuropsychiatric and cognitive testing questionnaires
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- University of Pennsylvania
Alzheimer Disease, Parkinson Disease
hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases
To evaluate the safety and preliminary efficacy of human umbilical cord mesenchymal stem cell-derived small extracellular vesicles hUC-MSC-sEV-001 nasal drops in multiple neurodegenerative diseases, including Alzheimer's disease…
- Conditions
- Alzheimer Disease, Parkinson Disease, Lewy Body Dementia, Multiple System Atrophy
- Trial name
- NCT06607900
- Testing
- hUC-MSC-sEV-001 nasal drops
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xuanwu Hospital, Beijing
Dementia, Alzheimer Disease
The Swedish BioFINDER 2 Study
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g.
- Conditions
- Dementia, Alzheimer Disease, Parkinson Disease, Lewy Body Disease
- Trial name
- BioFINDER2 (NCT03174938)
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau
- Where
- 2 sites in Sweden
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital